Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders : What Can We Learn for SARS-Cov-2 Vaccination Strategies?
Speeckaert, Reinhart (Universitair Ziekenhuis Gent)
Lambert, Jo (Universitair Ziekenhuis Gent)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Speeckaert, Marijn (Universitair Ziekenhuis Gent)
Lapeere, Hilde (Universitair Ziekenhuis Gent)
De Schepper, Sofie (Universitair Ziekenhuis Gent)
van Geel, Nanja (Universitair Ziekenhuis Gent)
Universitat Autònoma de Barcelona

Date:	2021
Abstract:	Large-scale vaccination strategies are currently being deployed against severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2). Whether systemic medication for skin diseases affects the efficacy of vaccination and whether temporary interruption or extension of the dosing interval is necessary is under debate. Most immunomodulating/immunosuppressive drugs only affect vaccine-induced immune responses to a limited or moderate extent, preserving sufficient immunity in most patients. Mycophenolate mofetil, Janus kinase inhibitors, and rituximab require a more cautious approach, and judicious timing of vaccination might be appropriate in patients receiving these treatments. It should be noted that, for most drugs except methotrexate, data on the length of the interruption period to restore vaccine-induced immune responses to normal levels are either very limited or absent. In these cases, only the drug half-life can be used as a practical guideline. In most patients, systemic medication can be continued through the vaccination process, although case-by-case decisions can be considered.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; altres ; Versió publicada
Published in:	Drugs in R&D, june 2021, p. 1-10, ISSN 1179-6901

DOI: 10.1007/s40268-021-00349-0
PMID: 34106430

10 p, 751.6 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Published articles